{"contentid": 488020, "importid": NaN, "name": "Takeda\u00e2\u0080\u0099s growth plan foresees revenues of ~$9 billion for GEM-BU in 2030", "introduction": "Japan\u00e2\u0080\u0099s largest rugmaker Takeda Pharma has outlined its ambition for above- market, double-digit revenue growth of its Growth and Emerging Markets Business Unit (GEM BU).", "content": "<p>Japan&rsquo;s largest rugmaker Takeda Pharma (TYO: 4502) has outlined its ambition for above- market, double-digit revenue growth of its Growth and Emerging Markets Business Unit (GEM BU).</p>\n<p>The revenue goal of 1 trillion yen (around $9 billion) by fiscal year2030 represents more than doubling of current revenues in GEM BU. This potential growth will be&nbsp;primarily&nbsp;driven by a balanced geographical focus and targeted portfolio investments in the company&rsquo;s highly innovative 14 Global Brands and Wave 1 pipeline assets.&nbsp;</p>\n<p>&ldquo;Building upon Takeda&rsquo;s global vision to bring long-term value to patients,&nbsp;society&nbsp;and shareholders, we have sharpened our regional strategy to deliver healthcare in geographies that include 85% of the world&rsquo;s population. As a purpose-led, patient-centric&nbsp;and values-based company, our portfolio combines innovative therapies with the right degree of scale to be competitive. Together with attractive market fundamentals and an executive team equipped to deliver strong business performance, we are committed to delivering sustainable revenue growth while increasing patient access to our life-saving 0and life-transforming treatments,&rdquo; said Ricardo Marek, president of Growth &amp; Emerging Markets Business Unit at Takeda.&nbsp;</p>\n<p>With 95% of GEM BU&rsquo;s current revenues coming from innovative treatments aligned with the company&rsquo;s five key business areas, GEM BU has an ambition to outpace forecasted market revenue growth for the region over the next ten years.</p>\n<h2><strong>Key source of revenues expected from emerging markets</strong></h2>\n<p>&ldquo;Emerging Markets will be a key source of revenue and momentum for Takeda over the next decade, with a strategy aligned to our global innovation focus,&rdquo; said Costa Saroukos, Takeda&rsquo;s chief financial officer, adding: &ldquo;Through targeted investments in the portfolio and key markets, we expect growth of the GEM BU to outpace the market for specialized, innovative treatments, as we expand our 14 global brands and launch our&nbsp;Wave 1 pipeline assets in the region.&rdquo;&nbsp;&nbsp;</p>\n<p>Takeda&rsquo;s GEM BU is targeting expansion in high growth markets such as Brazil, China and India. These markets are expected to provide strong platforms for continued growth of existing brands and upcoming launches of Takeda&rsquo;s Wave 1 pipeline assets across key therapeutic areas. China in particular is expected to be&nbsp;a significant growth driver for Takeda on a regional and global level,&nbsp;with the potential to&nbsp;deliver&nbsp;revenue growth at&nbsp;a compound annual growth rate of over 20% over the next five years.<sup>1</sup>&nbsp;&nbsp;</p>\n<p>Takeda&rsquo;s innovative R&amp;D engine is also expected to add potentially transformative therapies to the GEM BU&rsquo;s current portfolio. Among the Wave 1&nbsp;pipeline&nbsp;assets, Takeda&rsquo;s dengue vaccine candidate (TAK-003), developed to address the 390 million global dengue infections every year, is projected to be a significant growth driver for the region, with&nbsp;the&nbsp;majority of projected revenues coming from GEM BU.&nbsp;</p>\n<p>For sustainable growth in Emerging Markets, Takeda is committed to ensuring that patients get continued access to innovative medicines. This includes strengthening local health systems and prioritizing sustainable approaches to commercial operations. The recently published <a href=\"https://www.takeda.com/newsroom/newsreleases/2021/takeda-achieves-industry-leading-positions-in-2021-access-to-medicine-index/\">2021 Access to Medicine (AtM) Index</a> has ranked Takeda first in Governance of Access, highlighting its work in the strengthening of health systems and compliance.&nbsp;</p>", "date": "2021-03-12 10:39:00", "meta_title": "Takeda\u00e2\u0080\u0099s growth plan foresees revenues of ~$9 billion for GEM-BU in 20", "meta_keywords": "Takeda, Emerging markets, Growth, Revenues, Pipeline", "meta_description": "Takeda\u00e2\u0080\u0099s growth plan foresees revenues of ~$9 billion for GEM-BU in 2030", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 1, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-03-12 10:38:08", "updated": "2021-03-12 10:46:33", "access": NaN, "url": "https://www.thepharmaletter.com/article/takeda-s-growth-plan-foresees-revenues-of-9-billion-for-gem-bu-in-2030", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "takeda_hq_large.jpg", "image2id": "takeda_hq_small.jpg", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Pharmaceutical", "therapy area_tag": NaN, "topic_tag": "Asia Pacific, Financial, Focus On, Management, Research", "geography_tag": "Brazil, China, India, Japan", "company_tag": "Takeda", "drug_tag": NaN, "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-03-12 10:39:00"}